Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14356/3083Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Karki, Khem Bahadur | - |
| dc.contributor.author | Mo, Zhaojun | - |
| dc.date.accessioned | 2026-07-07T06:04:59Z | - |
| dc.date.available | 2026-07-07T06:04:59Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.uri | https://hdl.handle.net/20.500.14356/3083 | - |
| dc.description | NHRC Approval | en_US |
| dc.description.abstract | NA | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Society for Integrated Development Nepal (SOLID Nepal), Satdobato, Lalitpur, Nepal | en_US |
| dc.relation.ispartofseries | RES;01274 | - |
| dc.title | A multicenter, randomized, double-blinded, placebo-controlled Phase III trial to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19 vaccine (CHO cell) in adults aged 18 years and older | en_US |
| dc.type | Research report | en_US |
| Appears in Collections: | Approval Research Report (NHRC) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| RES01274_KAR_2022.pdf | Download Full Report. | 22.11 MB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.